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Reaction of 5,11,17,23-tetra-tert-butyl-dihydroxy-26,28-bis(2-pentoxy)calix[4]arene 
(L(OH)2(Opentyl)2) with [TiCl4] afforded the dichlorotitanoacalix[4]arene complex 
[TiCl2L(O)2(Opentyl)2] (1) in good yield. Hydrolysis of 1 led to the isolation of the complex 
{[TiL(O)3(Opentyl)]2(µ-OH)(µ-Cl)} (2). Reaction of 49,50,51,52,53,54,55,56-
octapropoxycalix[8]arene (L/(Opropyl)8) with [TiCl4] in refluxing toluene afforded, following 
work-up, a 35:65 mixture (3) of the complex [Ti(NCMe)Cl]2[TiCl(µ-O)]2L/] and the silicone 
grease derived complex [Ti(NCMe)Cl]2[Ti(µ-O)]2[OSi(CH3)2OSi(CH3)2O]L/] in which the 
grease replaces two chloride ligands. The molecular structures of 1∙2MeCN, 2∙7¼MeCN, 
and 3∙10MeCN have been determined.  The complexes were studied using in vitro cell assays 
and were found to have CC50 values in the range 111 - 186 µM, i.e. they have low toxicity. 
 
 
Introduction 
The biological potential of calix[n]arenes is now well recognised. [1] They have been 
utilized as scaffolds in the battles against TB, HIV and cancer as well as extensively as 
biosensors.[2] This interest stems from the ability to readily tune properties such as 
solubility and also from the ability to append functional groups/motifs of biological 
interest. In the case of metallocalixarenes, one important aspect to address is their 
hydrolytic stability and, in particular, whether or not the metal remains bound to the 
calixarene under physiological conditions. We are interested in exploiting the many 
attributes of calix[n]arenes to develop new scaffolds capable of selectivity for the 
receptors overexpressed on the surface of cancer cells.[2b, 3] Given that, despite it’s 
successes, cisplatin and derivatives such as carboplatin have major limitations, such as 
high instances of drug resistance, adverse side effects, and a tendency to only work 
against treatable cancers, there is a drive to develop new agents based on metals other 
than platinum. A number of titanium complexes bearing salen/salen-type ligation (see 
Chart 1) have been shown to exhibit promising anti-cancer effects, and have 
outperformed cisplatin.[4] In this study, we explore the potential of a 
dichlorotitanocalix[4]arene complex derived from a 1,3-dialkoxycalix[4]arene 
precursor and have identified a hydrolysis product. Extension of the work to a 
calix[8]arene system resulted in the isolation of a silicone grease derived complex. 
The incorporation if silicone grease into molecular structures has been reviewed. [5] 
Titanocalix[n]arenes are known, [6] but have only previously been exploited for their 
catalytic potential in α-olefin polymerization or the ring opening polymerization 
(ROP) of cyclic esters. [7] We also note that this type titanocalix[4]arene has been 
grafted onto silica and employed in olefin epoxidation by the group of Katz. [8]  
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Chart 1. The structures of a number of Ti-SALAN complexes that exhibit cytotoxicity 10 to 
20-fold greater than that of cisplatin. [4] 
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Chart 2. Titanocalix[n]arenes studied herein (R = tBu, L = NCMe). 
 
 
 
Results and Discussion 
Synthesis and characterisation 
The pro-ligand 5,11,17,23-tetra-tert-butyl-dihydroxy-26,28-bis(2-
pentoxy)calix[4]arene (L(OH)2(Opentyl)2) was prepared according to the previously 
described method. [3b, 7k] Refluxing a toluene solution of (L(OH)2(Opentyl)2) and 
[TiCl4] for several hours, followed by removal of solvent, extraction of the residue 
into warm acetonitrile and allowing the solution to cool and stand at ambient 
temperature afforded  deep red plates over the course of several days. A crystal 
suitable for a structure determination was chosen, and the molecular structure 
determined. The structure of [TiCl2L(O)2(Opentyl)2]•2MeCN (1) is shown in Figure 1; 
selected bond lengths and angles are given in the caption. 
 
Figure 1. Crystal structure of 1•2MeCN. The second MeCN is not visible due to 
modelling as a diffuse area of electron density. Selected bond lengths (Å) and angles 
(o): Ti(1)–O(1) 2.118(8), Ti(1)–O(2) 1.786(8), Ti(1)–O(3) 2.101(8), Ti(1)–O(4) 
1.805(8), Ti(1)–Cl(1) 2.342(4), Ti(1)–Cl(2) 2.334(4); Cl(1)–Ti(1)–Cl(2) 85.78(15), 
O(1)–Ti(1)–Cl(1) 92.8(2), O(1)– Ti(1)–O(3) 171.4(3). 
 The titanium centre is best described as distorted octahedral bound by two chlorides 
and four calixarene oxygen atoms, the calix[4]arene adopting a conformation with 
three rings ‘up’ and one ‘out’. The Ti–O phenolate bonds at 1.786(8) and 1.805(8) Å 
are typical and are significantly shorter than those of the Ti–O ether-type linkages 
[2.118(8) and 2.101(8) Å]. In the related structures [TiCl2LO2(OR)2] (R = Me, Et, nPr, 
iBu; CCDC refcodes: NIFQIC, XUSAK, XUWSEO, and XUWRUD respectively), the 
Ti–O(phenoxy) bond lengths are ca. 1.78 - 1.90 Å and Ti–O(ether) ca. 2.09 - 2.18 Å. 
[7k]  
In order to determine the air stability of 1, a solution of 1 was stirred under air for 2 h, 
whereupon following work-up, an orange/red complex was isolated. If the complex is 
taken up in acetonitrile, small prisms can be grown over several days. The molecular 
structure is shown in Figure 2, with selected bond lengths and angles given in the 
caption. The structure was identified as the complex {[TiL(O)3(Opentyl)]2(µ-OH)(µ-
Cl)} (2), which contains a bridging chloride and a bridging hydroxide ligand. The 
bridging hydroxide ligand may have been part chloride, but this was not modelled. 
Seven and a quarter acetonitrile solvate molecules complete the asymmetric unit to 
give a final formula of 2∙7¼MeCN. Each titanium centre in 2 again exhibits a 
distorted octahedral environment, and each is bound by a calix[4]arene ligand bearing 
only one pentoxy group. These pentoxy groups reside in trans positions above and 
below the Ti2(µ-OH)µ-Cl core. An acetonitrile molecule resides in each of the 
calix[4]arene cavities, whilst a further acetonitrile is involved in H-bonding to the 
bridging hydroxide group. Two and quarter other exo acetonitriles have been modelled 
as point atoms, and two exo acetonitriles were modelled as diffuse electron density by 
the Platon Squeeze procedure. [9, 10] We note that a route to monofunctionalised 
calix[4]arenes via removal of an ether functionality using TiCl4 has been reported by 
Floriani and coworkers. [6d] Floriani et al identified CH3Cl in their reaction and 
suggested this was the result of capture of the leaving group by the Cl- nucleophile. 
For 2, similar loss of two equivalents of pentylchloride is invoked and to balance the 
hydrolysis reaction, one equivalent of HCl is also lost. 
 
 
Figure 2. View of a molecule of {[TiL(O)3(Opentyl)](µ-OH)(µ-Cl)} (2∙7¼MeCN). 
Some MeCN molecules are not visible due to modelling as diffuse areas of electron density. 
Selected bond lengths (Å) and angles (o): Ti(1)–O(1) 2.363(7), Ti(1)–O(2) 1.814(6), Ti(1)–
O(3) 1.864(7), Ti(1)–O(4) 1.796(7), Ti(1)–Cl(1) 2.514(3), Ti(1)–O(9) 2.061(7); Cl(1)–Ti(1)–
Cl(2) 85.67(10), O(9)–Ti(1)–Cl(1) 90.2(3), O(1)–Ti(1)–O(3) 169.7(3), O(5)–Ti(1)–O(7) 
104.5(3). 
 
Use of 49,50,51,52,53,54,55,56-octapropoxycalix[8]arene (L/(Opropyl)8)  
Given the removal of the ether groups at the lower rim in calix[4]arene chemistry, we 
were interested to investigate how TiCl4 would react in combination with 
49,50,51,52,53,54,55,56-octapropoxycalix[8]arene (L/(Opropyl)8). On heating a 
toluene solution of (L/(Opropyl)8) and [TiCl4] for several hours and then, following 
removal of solvent, extracting the residue into warm acetonitrile red needles grew over 
the course of several days. In the 1H NMR spectrum, there was no evidence of propyl 
groups whilst a peak at δ 0.14 ppm was initially thought to be silicone grease. 
Surprisingly, a molecular structure determination revealed a calix[8]arene ligand 
binding four titanium centres (Figures 3 & 4), the latter forming a three step Ti4O4 
ladder central moiety (Figures 5 & 6). The central two titanium atoms were either 
coordinated to one chloride ion each (34.6(3) % occupancy), or linked by a 
OSi(Me)2OSi(Me)2O (65.4(3) % occupancy) which accounts for the peak at δ 0.14 
ppm in the 1H NMR spectrum, and is thought to originate from the use of silicone 
grease. We note that silicone grease has proved to be a source of some interesting 
coordination complexes. [5, 9] Two chlorides and two bound MeCN solvate molecules 
complete the structure of 3∙10MeCN with 10 unbound MeCNs also present. 
 
 
Figure 3. Top view of a molecule of [Ti(NCMe)Cl]2[TiCl]2[μ-
O]2[5,11,17,23,29,35,41,47-tetra-tert-butyl-49,50,51,52,53,54,55,56-
octaoxocalix[8]arene] in 3∙10MeCN. MeCN of crystallisation omitted for clarity. 
Selected bond lengths (Å) and angles (o): Ti(1)–O(3) 1.9502(16), Ti(1)–O(4) 
1.7828(16), Ti(1)–O(5) 1.9967(16), Ti(1)–O(5A) 1.9026(16), Ti(1)–Cl(2X) 2.269(3), 
Ti(2)–O(1) 1.8118(16); Ti(2)–O(2) 1.8180(16), Ti(2)–O(3) 2.1713(15), Ti(2)–O(5) 
1.9464(17), Ti(2)–N(1) 2.276(2), Ti(2)–Cl(1) 2.2981(8), Cl(2X)–Ti(1)–O(5) 
105.08(10), O(3)–Ti(1)–O(5) 76.37(7), O(3)–Ti(2)–O(5) 72.45(6), Cl(1)–Ti(2)–O(5) 
96.01(6), Cl(1)–Ti(2)–N(1) 174.14(14). 
 
 
Figure 4. Side view of a molecule of [Ti(NCMe)Cl]2[Ti]2[μ-O]2[μ-
OSi(CH3)2OSi(CH3)2O][5,11,17,23,29,35,41,47-tetra-tert-butyl-
49,50,51,52,53,54,55,56-octaoxocalix[8]arene] in 3∙10MeCN. MeCN of 
crystallisation omitted for clarity. 
 
 
 Figure 5. View of the core Ti4O4 ladder moiety present in (3∙10MeCN) showing the 
molecule with four chlorides, and two MeCNs. 
 
 
Figure 6. View of the core Ti4O4 ladder moiety present in (3∙10MeCN) showing the 
molecule with the disiloxane bridge, two chlorides, and two MeCNs. 
 
Cytotoxicity studies 
The complexes presented were tested for cytotoxicity against a tumour cell line to see 
if the compounds had anticancer properties in their current form. The cytotoxicity 
values were measured using a cell viability assay. It should be noted that in in vivo and 
clinical tests formulation is key for cytotoxicity, especially for stable compounds. It 
has been observed in previous studies that the time the titanium compounds remain in 
solution can have an impact on the properties as hydrolysis occurs to form insoluble 
materials.  
 Complexes (1) - (3) were tested for their anti-proliferative activity against U-87 
cells. These cells were incubated for 72 h before determining their mitochondrial 
based reduction of a tetrazolium dye (MTS) to a formazan product which absorbs at 
490 nm. This experiment was carried out over a range of concentrations to determine 
the amount of compound required to reduce cell growth by 50% (cytotoxic 
concentration, CC50). All compounds in this study are relatively non-toxic with CC50 
values in the range 111-186 µM. Dose response curves for treatment of U-87 cells 
with compounds (1) - (3) are shown in Figure 7. 
 
 
 Figure 7. Dose response curve for 1, 2 and 3 showing the cell viability of MCF-7 cells on 
exposure to increasing concentrations of the titanium calixarene compounds. The CC50 values 
show the concentrations at which 50% of the cell population is no longer viable based on the 
curves plotted. 
 
When compared with some titanium based anti-cancer agents, there are more effective 
monomeric compounds in the literature, particularly among the phenolato 
derivatives.[10] As a comparator, cisplatin, gives IC50 values between 10 - 20 μM 
depending on which cell line the assay is run. A bis(β-diketonato)titanium complex 
((bzac)2Ti(OiPr)2) shows an IC50 value between 11 - 12 μM and a series of Ti-SALAN 
complexes (Chart 1) gives IC50 values from 1 - 10 μM. Table 1 summarises the CC50 
values of the complexes synthesised and the IC50 values of selected Ti based anti-
cancer agents [10(a)].  
It is interesting to note the variation in compound properties relative to formulation 
and the relationship between hydrolytic stability and cytotoxicity. [10(b,c,d)] For 
example, it has been shown for some of the titanium(IV) salan compounds that 
switching a 2,4-di-tert-butyl phenol component to a 2,4-dimethyl phenol component 
activates the compounds against cancer cell lines by targeting of the cytoskeleton. 
[10(a)] Despite the lack of cytotoxic properties in this assay it is likely that 
modification of the structures and tuning of the stability could be combined with 
suitable formulation to deliver bioactive compounds. It is also worth noting that other 
mechanisms can give anticancer activities that would only become apparent in in vivo 
studies. Further research is required to determine optimal structural types for 
titanium(IV) calixarenes in biological applications. It would also be of interest to 
screen the compounds in antimicrobial analyses to determine activity against different 
organisms. 
 
Complex CC50 (μM) 
(1) 111.3 (U-87) 
(2) 155.8 (U-87) 
(3) 185.5 (U-87) 
Known Compound IC50 (μM)[11] 
Cisplatin 20 (HT-29), 19 (OVCAR-1) 
Cp2TiCl2 520 (HT-29), 550 (OVCAR-1) 
(bzac)2Ti(Oipr)2 11.6 (HT-29), 11.5 (OVCAR-1) 
Lig1Ti(OArMe2)2 10 (HT-29), 9 (OVCAR-1) 
Lig2Ti(OArMe2)2 3.5 (HT-29), 3.3 (OVCAR-1) 
Lig3Ti(OArMe2)2 1.2 (HT-29), 1.0 (OVCAR-1) 
Table 1 - CC50 (μM) values of the Ti complexes synthesised and IC50 (μM) values of a 
selected Ti complexes. 
Table 2. Crystal data for 1∙2MeCN, 2∙7¼MeCN, and 3∙10MeCN. 
 
Compound 1∙2MeCN 2∙7¼MeCN 3∙10MeCN 
 
Formula 
 
C54H74Cl2O4Ti∙2MeCN C98H127ClO9Ti2∙7.25(MeN) 
[C92H110Cl4N2O10Ti4]0.346 
[C96H122Cl2N2O13Si2Ti4]0.654 
∙10MeCN 
Formula weight 988.0 1877.88 2207.32 
Crystal system Monoclinic Monoclinic Monoclinic 
Space group A2 P21/n C2/c 
Unit cell dimensions    
a  (Å) 17.2312(16) 26.816(2) 31.7283(3) 
b  (Å) 12.1620(8) 13.2305(9) 14.26944(14) 
c  (Å) 27.103(2) 32.648(3) 28.7967(3) 
β (Å) 101.229(9) 104.480(3) 111.2143(12) 
V  (Å3) 5571.2(8) 11215.2(15) 124154.1(2) 
Z 4 4 4 
Temperature (K) 140(2) 120(2) 100(2) 
Wavelength (Å) 0.71073 0.71073 0.71073 
Calculated density 
(Mg m-3) 1.178 1.112 1.206 
Absorption 
coefficient (mm-1) 0.30 0.22 0.39 
Transmission 
factors (min/max) 0.914 and 0.974 0.940 and 0.993 0.863 and 1.000 
Crystal size (mm3) 0.31 × 0.21 × 0.09 0.28 × 0.09 × 0.03 0.35 × 0.12 × 0.03 
θ (max) (°) 22.5 22.5 27.5 
Reflections 
measured 30661 35666 97082 
Unique reflections 7245 12068 13919 
Rint 0.144 0.087 0.026 
Reflections with F2 > 
2σ(F2) 3472 7470 13137 
Number of 
parameters 592 1299 804 
R1 [F2 > 2σ(F2)] 0.067 0.122 0.057 
wR2 (all data) 0.144 0.275 0.147 
GOOF, S 0.82 1.06 1.18 
Largest difference 
peak and hole (e Å-
3) 
0.42 and –0.27 0.50 and –0.38 1.01 and –0.65 
    
 
  
Conclusion 
Three titanocalixarene complexes have been synthesised, characterised and screened for their 
anti-proliferative activity. The biological screening assay gives CC50 values that did not show 
significant anticancer activity for these compounds against the breast cancer cell line tested 
(U87). However, alternate formulation of the compounds or minor structural changes may 
alter their intracellular distribution and capability to form bioactive clusters. Calixarenes 
present a suitable framework for modification and so further investigation is required of 
alternate derivatives and formulation. 
Experimental section 
General remarks 
NMR spectra were recorded on a Jeol JNM ECP400 spectrometer and a Jeol JNM-
LA400, with TMS δH = 0 ppm as the internal standard or residual protic solvent 
[CDCl3, δH =7.26]. Chemical shifts are given in ppm (δ) and coupling constants (J) are 
given in Hertz (Hz). Peak types in the spectra are denoted by the following notations: 
broad (br), singlet (s), doublet (d), triplet (t), quartet (q), quintet (quin), sextet (sex), 
and multiplet (m). Elemental analyses were carried out by staff at the University of 
Hull. Infrared spectra were recorded on a Nicolet iS5 FT-IR spectrometer. Mass 
spectra were obtained from the EPSRC National Mass Spectrometry Service Unit, 
Swansea University. 
5,11,17,23-tetra-tert-butyl-dihydroxy-26,28-bis(2-pentoxy)calix[4]arene 
(L(OH)2(Opentyl)2) and 49,50,51,52,53,54,55,56-octapropoxycalix[8]arene 
(L/(Opropyl)8) were prepared using the previously reported methods. [3b, 11] TiCl4 
(1M in dichloromethane) was obtained from Sigma-Aldrich Company Ltd. and used as 
received. 
 Synthesis of [TiCl2L(O)2(Opentyl)2] (1) 
To a solution of 5,11,17,23-tetra-tert-butyl-25,27-bis(pentoxy)-26,28-
dihydroxycalix[4]arene (2.5 g, 3.2 mmol) in warm, anhydrous toluene (50 mL) was 
added titanium(IV) chloride (1.0 M in toluene, 3.2 mL, 3.2 mmol). The resulting deep 
red solution was stirred at reflux for 6 h under a nitrogen atmosphere. The volatiles 
were then removed in vacuo and the residue was extracted into warm anhydrous 
acetonitrile (20 mL). The resulting solution was filtered under nitrogen whilst still 
warm and allowed to cool to room temperature. The solution was left to stand at 
ambient temperature and over the course of six to seven days dark red crystals were 
deposited. The remaining solution was decanted and further crops of crystals were 
obtained from this solution to give a total yield of 1.22 g (42.5%). 1H NMR (400 MHz; 
CDCl3; sample dried in-vacuo for 12 h, -2MeCN) δ: 7.19 (4 H, s, ArylH), 6.89 (4 H, s, 
ArylH), 5.05 (4 H, t, J = 8, OCH2CH2), 4.89 (4 H, d, J = 12, endo-CH2), 3.25 (4 H, d, 
J = 12, exo-CH2), 2.03 (4 H, m, OCH2CH2CH2CH2CH3), 1.42 (18 H, s, (C(CH3)3)), 
1.03 (8 H, m, OCH2CH2CH2CH2CH3), 0.70 (18 H, s, (C(CH3)3)), 0.69 (6 H, t, J = 8, 
CH2CH3). MALDI-MS m/z 780.38 [M+H]+. Found: C, 70.58; H, 8.40; N, 2.71%. 
Calcd. for C54H74Cl2O4Ti·2(CH3CN): C, 70.51; H, 8.16; N, 2.84%. IR (νmax/cm–1) 
2954 (w), 2923 (s), 2854 (m), 2360 (w), 1459 (s), 1377 (s), 1302 (w), 1260 (s), 1200 
(w), 1090 (s), 1019 (s), 871 (w), 798 (s), 721 (m), 668 (w), 618 (w), 571 (m), 525 (m), 
497 (m), 453 (m), 424 (s). 
 
Synthesis of {[TiL(O)3(Opentyl)]2(µ-OH)(µ-Cl)} (2) 
A sample of 1 (0.50 g, 0.60 mmol) was exposed to atmospheric conditions for 2 h. The 
resulting solid was then extracted into warm, anhydrous acetonitrile (10 mL) and 
filtered under a nitrogen atmosphere. The solution was left to stand at ambient 
temperature. Over the course of three to four days small orange/red prisms were 
deposited (0.18 g, 41.3%). 1H NMR (400 MHz; CDCl3; sample dried in-vacuo for 12 
h, -7.25MeCN) δ: 7.02 (4 H, s, ArylH), 6.74 (4 H, s, ArylH), 5.13 (2 H, t, J = 8, 
OCH2CH2), 4.95 (4 H, d, J = 12, endo-CH2), 3.25 (4 H, d, J = 12, exo-CH2), 2.78 (2 H, 
m, OCH2CH2CH2CH2CH3), 1.35 (18 H, s, (C(CH3)3)), 0.92 (4 H, m, 
OCH2CH2CH2CH2CH3), 0.84 (18 H, s, (C(CH3)3)), 0.58 (3 H, t, J = 8, CH2CH3). 
MALDI-MS m/z 1579.89 [M+H]+. Found: C, 74.02; H, 8.01; N, 1.34%. Calcd. for 
C98H127ClO9Ti2·1.5(CH3CN): C, 73.89; H, 8.07; N, 1.28%. IR (νmax/cm–1) 2954 (w), 
2924 (s), 2854 (m), 2726 (w), 1459 (s), 1377 (s), 1304 (w), 1261 (m), 1209 (w), 1154 
(w), 1093 (m), 1019 (m), 968 (w), 936 (w), 918 (w), 889 (w), 873 (w), 796 (m), 721 
(m), 555 (w). 
 
 
Synthesis of 0.346[Ti(NCMe)Cl]2[Ti]2[μ-O]2[Cl][5,11,17,23,29,35,41,47-tetra-tert-butyl-
49,50,51,52,53,54,55,56-octaoxocalix[8]arene]:0.654[Ti(NCMe)Cl]2[Ti]2[μ-O]2[μ-
OSi(CH3)2OSi(CH3)2O][5,11,17,23,29,35,41,47-tetra-tert-butyl-49,50,51,52,53,54,55,56-
octaoxocalix[8]arene]   (3) 
To a suspension of L/(Opropyl)8  (2.00 g, 1.22 mmol) in anhydrous toluene (25 mL) was 
added titanium(IV) chloride (1.0 M in toluene, 5.00 mL, 5.00 mmol). The resulting deep red 
mixture was refluxed for 16 h under an inert atmosphere. The volatiles were then removed in 
vacuo and the resulting residue was extracted into warm, anhydrous acetonitrile (20 mL). The 
solution was filtered whilst warm under inert conditions and the filtrate was allowed to cool. 
The filtrate was left to stand for 7 days at ambient temperature during which time red needles 
of the co-crystallised compounds formed (0.96 g, 43%). δH (400 MHz; CDCl3; sample dried 
in-vacuo for 12h, -10MeCN) 7.26 (2 H, d, J = 4, ArylH), 7.23 (2 H, d, J = 4, ArylH), 7.21 (2 
H, d, J = 4, ArylH), 7.16 (4 H, m, ArylH), 6.84-6.82 (4 H, 2x m, ArylH), 4.99 (1 H, d, J 12.0 
Hz, endo-CH2), 4.88 (1 H, d, J 12.0 Hz,  endo-CH2), 4.72 (2 H, d, J 16.0 Hz,   endo-CH2), 
4.64 (4 H, m, endo-CH2), 4.01-3.83 (2 H, m, exo-CH2), 3.59 (1 H, d, J 12.0 Hz, exo-CH2), 
3.54 (1 H, d, J 12.0 Hz, exo-CH2), 3.36 (2 H, m, exo-CH2), 3.29 (2 H, d, J 12.0 Hz, exo-CH2), 
1.35 (18 H, s, C(CH3)), 1.33 (18 H, s, C(CH3)),  1.18 (18 H, s, C(CH3)), 1.17 (18 H, s, 
C(CH3)), 0.14 (s, ca 5.4H, SiMe2). ES-MS m/z 1748 (Siloxide [M]+ - 2MeCN), 1702 
(Chloride [M]+ - Cl). Found: C, 61.02; H, 6.67; N, 1.49%. [12] 
[C92H110Cl4N2O10Ti4]0.346[C96H122Cl2N2O13Si2Ti4]0.654 (sample dried in-vacuo for 12h, -
10MeCN) requires: C, 63.24; H, 6.53; N, 1.56%. IR (νmax/cm–1) 2962 (m), 2905 (w), 1599 
(w), 1452 (w), 1412 (w), 1361 (w), 1258 (s), 1191 (w), 1077 (m), 1011 (s), 863 (m), 789 (s), 
696 (m), 660 (m).  
 
Crystal structure determinations. 
Further details are given in Table 2, with special details pertaining to the three crystal 
structures summarised here. Crystals suitable for X-ray diffraction were grown by leaving 
saturated solutions of complexes (1) – (3) in anhydrous MeCN to stand at ambient 
temperature for several days. For 1∙2MeCN, a deep red plate crystal was immediately coated 
in a thin layer of perfluoropolyether to avoid oxidation/hydrolysis of the product. An Oxford 
Diffraction Xcalibur CCD diffractometer was used for data collection. For 1∙2MeCN the 
Platon Squeeze procedure was used to model one of the two unique MeCN molecules of 
crystallisation. [13 -15] For 2∙7¼MeCN the Platon Squeeze procedure was used to model two 
of the unique MeCN molecules of crystallisation with some MeCNs modelled as point atoms 
but with two-fold disorder or with partial occupancy. There is disorder in three of the tBu 
groups of the calixarenes with all of the methyl groups split over two sets positions: at C(18) 
the major occupancy = 67.6(18)%, at C(51) the major occupancy = 58.5(14)%, and at C(84) 
the major occupancy = 62(4)%. For 3∙10MeCN data were collected using a Rigaku 
diffractometer with a rotating anode and Rigaku Saturn724+ detector. The complex lies on a 
centre of symmetry and is a solid-solution of the tetrachloride and dichloride/disiloxane 
complexes in a 34.6:65.4(3)% ratio respectively. Several of the MeCNs of crystallisation 
were modelled as disordered or partially occupied, which is least partly a result of the main 
complex disorder and the different volumes occupied by the two forms. 
 
Cytotoxicity 
MTS assay is based upon the conversion of tetrazolium salt to into formazan in viable 
cells via mitochondrial dehydrogenase enzyme activity. The amount of formazan is 
directly proportional to the number of viable cells in the culture media. U-87 (homo 
sapiens brain glioblastoma) cells were seeded in 96 flat bottomed microtiter tissue 
culture plates with 1000 cells/well in 200 μL media (RPMI + 1% glutamine + 10% 
FCS). The plates were incubated overnight in a 5% CO2 incubator at 37°C to allow 
cells to adhere. The next day the media was removed from the wells and 100 μL 
compound in media was added. Tested compounds were used in a range of 
concentrations from 0.91 μM to 2 mM. The plates were then returned to a 5% CO2 
incubator for 72 h after which MTS reagent (Promega, UK) 20 μL was added to each 
well and returned to the incubator at 37°C for a further 3 h. Absorbance readings were 
taken at 490 nm using a Synergy HT microplate reader (Biotek, USA). Experiments 
were carried out in triplicate and subtracted from media only absorbance.  CC50 values 
were obtained using GraphPad Prism 5 (GraphPad, USA) software. 
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